BRIEF—BioMarin highlights breadth of pipeline at R&D Day

California, USA-based BioMarin Pharmaceutical updated the investment community today on the company's research and development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.

"BioMarin is poised to deliver multiple research, development and regulatory milestones in 2019 driven by the tremendous productivity of our R&D organization. We continue to tap into our deep experience and knowledge in rare genetic diseases to advance our pipeline programs, while also demonstrating the long-term benefit to patients of our recently approved therapies like Palynziq [pegvaliase-pqpz] and Brineura [cerliponase alfa]," said Dr Hank Fuchs, president worldwide R&D of BioMarin.

"By concentrating on the underlying pathology of disease, we're able to increase our odds of demonstrating meaningful and sustained outcomes. Our next potential commercial prospects include vosoritide, valoctocogene roxaparvovec and European regulatory approval for Palynziq,” he added.

Full press release can be accessed on this link:

https://www.prnewswire.com/news-releases/biomarin-highlights-breadth-of-innovative-development-pipeline-at-rd-day-on-november-7th-in-new-york-300745521.html